Australian health authorities expect to conclude their safety review of cannabidiol in low doses in March, the results of which could inform any decision to down-schedule the popular cannabinoid.

Any move to reschedule certain doses of CBD, making it available over the counter, could open the door to new market opportunities for businesses.